SIM0813

SIM0813 is an antibody-drug conjugate (ADC) currently under development by Shandong Simcere Medgenn, a subsidiary of Simcere Pharmaceutical. The drug is designed to target Leucine-rich repeat-containing protein 15 (LRRC15), a cell surface protein that is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor stroma and on certain mesenchymal-like tumor cells, while remaining largely absent from normal tissues. By specifically binding to LRRC15, SIM0813 facilitates the targeted delivery of a cytotoxic payload to the tumor microenvironment, aiming to exert potent anti-tumor activity and potentially overcome stroma-mediated resistance in various solid tumors.